Rapid Discovery! Accelerate drug discovery from hit ID to the clinic

Mounting competitive pressure is forcing the biopharma industry to look at new ways to shorten the time scale for all aspects of drug discovery. High throughput screening (HTS) has emerged as a key enabler in accelerating drug discovery. This is due to its ability to test and identify a large number of compounds quickly and efficiently.

However, effective integration of compound supply, assay operation, and data management are essential to achieve the necessary productivity. To discuss these considerations and more, Syngene, in association with Axcelead Drug Discovery Partners, Inc. brings you an interactive virtual webinar on ‘Rapid Discovery’ and how to accelerate drug discovery – hit identification to the clinic.

📌Topics covered during the webinar
⦿ High throughput screening and approaches for efficient hit identification
⦿ Post HTS: Data analysis and interpretation
⦿ Hit to clinic journey: Important milestones and considerations

#drugdiscovery #HTS #webinar